Adicet Bio, Inc. (0HX7.L)

USD 0.68

(0.39%)

Long Term Debt Summary of Adicet Bio, Inc.

  • Adicet Bio, Inc.'s latest annual long term debt in 2023 was 17.7 Million USD , down -4.47% from previous year.
  • Adicet Bio, Inc.'s latest quarterly long term debt in 2024 Q1 was 16.71 Million USD , down 0.0% from previous quarter.
  • Adicet Bio, Inc. reported annual long term debt of 18.53 Million USD in 2022, down -4.37% from previous year.
  • Adicet Bio, Inc. reported annual long term debt of 19.37 Million USD in 2021, down -5.13% from previous year.
  • Adicet Bio, Inc. reported quarterly long term debt of - USD for 2024 Q2, down 0.0% from previous quarter.
  • Adicet Bio, Inc. reported quarterly long term debt of 18.66 Million USD for 2023 Q3, down -4.76% from previous quarter.

Annual Long Term Debt Chart of Adicet Bio, Inc. (2023 - 2017)

Historical Annual Long Term Debt of Adicet Bio, Inc. (2023 - 2017)

Year Long Term Debt Long Term Debt Growth
2023 17.7 Million USD -4.47%
2022 18.53 Million USD -4.37%
2021 19.37 Million USD -5.13%
2020 20.42 Million USD -82.1%
2019 114.08 Million USD 3564.73%
2018 3.11 Million USD 0.0%
2017 - USD 0.0%

Peer Long Term Debt Comparison of Adicet Bio, Inc.

Name Long Term Debt Long Term Debt Difference
uniQure N.V. 130.06 Million USD 86.389%
Agios Pharmaceuticals, Inc. 56.98 Million USD 68.936%
Amicus Therapeutics, Inc. 387.85 Million USD 95.436%
Atara Biotherapeutics, Inc. 45.69 Million USD 61.257%
bluebird bio, Inc. 224.41 Million USD 92.112%
Cara Therapeutics, Inc. 37.07 Million USD 52.256%
Imunon, Inc. 1.13 Million USD -1453.858%
Editas Medicine, Inc. 24.37 Million USD 27.363%
IQVIA Holdings Inc. 12.95 Billion USD 99.863%
Mettler-Toledo International Inc. 1.97 Billion USD 99.104%
Myriad Genetics, Inc. 130.9 Million USD 86.476%
Neurocrine Biosciences, Inc. 258.3 Million USD 93.146%
Supernus Pharmaceuticals, Inc. 33.19 Million USD 46.671%
Verastem, Inc. 40.08 Million USD 55.837%
Walgreens Boots Alliance, Inc. 8.04 Billion USD 99.78%
Waters Corporation 2.3 Billion USD 99.232%
Thermo Fisher Scientific Inc. 31.3 Billion USD 99.943%
Biogen Inc. 7.18 Billion USD 99.754%
Nektar Therapeutics 112.62 Million USD 84.281%
Perrigo Company plc 3.63 Billion USD 99.513%
Dynavax Technologies Corporation 252.41 Million USD 92.987%
Illumina, Inc. 1.48 Billion USD 98.811%
Corbus Pharmaceuticals Holdings, Inc. 3.23 Million USD -446.62%
Iovance Biotherapeutics, Inc. 1 Million USD -1670.3%
Heron Therapeutics, Inc. 173.75 Million USD 89.811%
Unity Biotechnology, Inc. 23.53 Million USD 24.793%
BioMarin Pharmaceutical Inc. 593.09 Million USD 97.015%
Sangamo Therapeutics, Inc. 33.51 Million USD 47.179%
Evolus, Inc. 120.35 Million USD 85.292%
Aclaris Therapeutics, Inc. 3.07 Million USD -475.895%
Regeneron Pharmaceuticals, Inc. 2.7 Billion USD 99.345%
Esperion Therapeutics, Inc. 501.54 Million USD 96.47%
FibroGen, Inc. 89.69 Million USD 80.264%
Agilent Technologies, Inc. 2.73 Billion USD 99.353%
OPKO Health, Inc. 222.03 Million USD 92.027%
Homology Medicines, Inc. 43.17 Million USD 58.998%
Geron Corporation 35.05 Million USD 49.494%
Alnylam Pharmaceuticals, Inc. 2.34 Billion USD 99.244%
Exelixis, Inc. 189.94 Million USD 90.68%
Viking Therapeutics, Inc. 936 Thousand USD -1791.346%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 96.74 Million USD 81.702%
Zoetis Inc. 6.56 Billion USD 99.73%
Axsome Therapeutics, Inc. 178.07 Million USD 90.058%
Abeona Therapeutics Inc. 4.4 Million USD -302.158%
Vertex Pharmaceuticals Incorporated 724.7 Million USD 97.557%
Kala Pharmaceuticals, Inc. 34.19 Million USD 48.222%
Ionis Pharmaceuticals, Inc. 1.4 Billion USD 98.736%
Sarepta Therapeutics, Inc. 1.13 Billion USD 98.437%
Corcept Therapeutics Incorporated - USD -Infinity%
Halozyme Therapeutics, Inc. 1.49 Billion USD 98.819%
Blueprint Medicines Corporation 610.96 Million USD 97.102%
Insmed Incorporated 1.19 Billion USD 98.517%
TG Therapeutics, Inc. 100.11 Million USD 82.318%
Incyte Corporation 29.16 Million USD 39.294%
Emergent BioSolutions Inc. 446.5 Million USD 96.035%